How to appeal a UnitedHealthcare vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters

Cited policy: UHC Commercial Medical Policy: Endovascular Repair of Abdominal Aortic Aneurysm

Infrarenal AAA >=5.5cm in men or >=5.0cm in women on CTA; OR rapid growth (>=0.5cm in 6 mo); OR symptomatic / tender / saccular. Anatomy within FDA IFU for selected endograft. Reasonable surgical / anesthetic candidacy.

How UnitedHealthcare denies vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters — and how to counter it

Where UnitedHealthcare pushes back: 1) Diameter below threshold; 2) IFU compliance not demonstrated in CTA report; 3) Endograft brand not on plan formulary.

Counter-arguments that hold up: Submit CTA planning report with each IFU parameter (neck length, neck angulation, neck thrombus, common iliac diameter, suprarenal angle) explicitly compared to device IFU. Cite SVS 2018 AAA Guideline (Chaikof JVS 2018;67(1):2). For sub-threshold AAA cite rapid growth or saccular morphology with imaging documentation. Cite EVAR-1 / DREAM / OVER 30-day mortality benefit.

What UnitedHealthcare typically denies for vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the vascular & endovascular — aaa, carotid, pad, varicose veins, ivc filters treatments most often flagged for prior auth, step therapy, or medical necessity review:

• EVAR (AAA)
• F-EVAR / B-EVAR
• Open AAA repair
• TEVAR
• CEA
• CAS (transfemoral)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.